Financial Performance - The company's operating revenue for 2024 reached ¥2,817,158,242.24, representing a year-on-year increase of 34.13% compared to ¥2,100,322,880.68 in 2023[21]. - The net profit attributable to shareholders for 2024 was ¥827,602,233.89, reflecting a 49.00% increase from ¥555,449,411.27 in 2023[23]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥826,964,773.08, up 42.73% from ¥579,389,975.10 in 2023[23]. - The net cash flow from operating activities decreased by 15.91% to ¥430,633,178.42 in 2024, down from ¥512,100,798.56 in 2023[23]. - The company's total assets increased by 29.47% to ¥3,050,414,835.58 at the end of 2024, compared to ¥2,356,087,094.17 at the end of 2023[21]. - The net assets attributable to shareholders grew by 36.08% to ¥2,553,316,291.75 at the end of 2024, up from ¥1,876,401,342.72 at the end of 2023[21]. - Basic earnings per share for 2024 were ¥2.03, a 48.18% increase from ¥1.37 in 2023[22]. - The gross margin for antiviral drugs was 96.22%, with a year-on-year increase of 0.70 percentage points[115]. - The company reported a total revenue of 1,730,779,000.00 RMB, with a net profit of 342,487,793.87 RMB, representing a significant increase in performance compared to the previous period[89]. Research and Development - The R&D expenditure as a percentage of operating revenue was 12.16% in 2024, down from 13.33% in 2023[22]. - Research and development investment for 2024 was 342 million RMB, an increase of 22.34% year-on-year[32]. - The company reported a total R&D investment of approximately ¥342.49 million, an increase of 22.34% compared to the previous year[85]. - The company has filed for 20 new patents this year, with a total of 309 patents filed cumulatively[83]. - The company has established a core technology platform for PEG modification of recombinant protein drugs, which enhances drug efficacy and reduces immunogenicity[79]. - The company is focusing on integrating full industry chain capabilities to enhance its competitive position in the recombinant protein drug market[77]. - The company is actively pursuing new product development and market expansion strategies in the biopharmaceutical sector[150]. - The company is committed to increasing R&D investment and enhancing independent innovation capabilities to mitigate risks associated with drug development failures[101]. Market Strategy and Growth - The company plans to continue expanding its market presence and improving operational management to enhance profitability[23]. - The company aims to become a leader in systemic immune solutions based on cytokine drugs, particularly in the field of hepatitis B clinical cure[39]. - The company is focusing on enhancing organizational efficiency and risk management to support sustainable business operations[35]. - The company is actively involved in various public welfare and research projects aimed at improving treatment options for hepatitis B patients[31]. - The company has signed multiple collaboration agreements to expand its product pipeline in liver disease prevention and treatment, including a research cooperation agreement with Aligos Therapeutics in May 2023[34]. - The company is closely monitoring market dynamics to enhance cost control and improve product competitiveness amid potential procurement challenges[160]. - The company is focusing on the immune and metabolic fields, aiming to enhance clinical value through innovation and service upgrades[179]. Corporate Governance and Compliance - The audit report issued by the accounting firm is a standard unqualified opinion[4]. - The company has not violated decision-making procedures for external guarantees[8]. - The company does not have any special arrangements for corporate governance[8]. - The company emphasizes risk prevention and compliance training to enhance employee awareness and response capabilities[37]. - The company has established a public opinion management system to effectively handle various public relations issues and protect investor rights[187]. - The company has revised its governance structure and internal rules to optimize decision-making efficiency and quality[185]. - The company maintains clear responsibilities and independence from its major shareholders, ensuring no conflicts of interest arise[188]. Risk Management - The company has detailed potential risks and countermeasures in the report, emphasizing the importance of risk awareness for investors[6]. - The company faces risks related to technological upgrades and iterations, which could impact its core competitiveness if revolutionary discoveries occur in related fields[99]. - The company is at risk of not winning bids or experiencing price declines in drug procurement, which could negatively affect sales revenue and net profit[102]. - The company plans to strengthen its market information monitoring and optimize its internal control systems to enhance risk resilience[106]. Product Development and Innovation - The company is focusing on the clinical cure of hepatitis B, with a new indication application for its key product, Pegb interferon, accepted by the National Medical Products Administration in March 2024[31]. - The company has launched five products, including Paigebin, which is recognized as a first-line antiviral treatment for chronic hepatitis B[39]. - The company is preparing for Phase III clinical research of the YPEG-EPO project, while the new indications for Paigebin and Peijin have received clinical trial approvals in July 2024 and January 2025, respectively[34]. - The company has completed clinical research for the drug Peginterferon α-2b and is applying for an indication expansion to treat chronic hepatitis B patients by March 2024[150]. - The company is conducting Phase I clinical trials for a new interferon aerosol spray aimed at reducing the risk of infection after exposure to COVID-19[150]. Investor Relations - The company actively engages with investors through various channels, including meetings and online platforms, to address their needs and enhance confidence in the company[187]. - The company emphasizes transparent information disclosure, ensuring compliance with relevant laws and regulations while providing accurate financial reports and significant updates to investors[186]. - The company has established a talent supply system to enhance key position talent density and drive innovation through personalized training and development plans[96]. Human Resources - The number of R&D personnel increased to 465, accounting for 19.19% of the total workforce, while the average salary for R&D staff was 24.50 thousand RMB[92]. - The company has reported a significant increase in R&D personnel compensation, totaling 10,751.10 thousand RMB, reflecting its commitment to talent development[92]. - The remuneration scheme for senior management is based on industry standards and individual performance assessments[197].

证券代码：688278 证券简称：特宝生物 公告编号：2025-009 厦门特宝生物工程股份有限公司 2024 年度利润分配预案的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 一、利润分配方案内容 （一）利润分配方案的具体内容 经容诚会计师事务所（特殊普通合伙）审计，厦门特宝生物工程股份有限公 司（以下简称"公司"）2024 年度实现归属于公司股东的净利润为 827,602,233.89 元，截至 2024 年 12 月 31 日，母公司报表期末未分配利润为 1,253,562,859.44 元。 经董事会决议，本次利润分配预案如下： 2024 年度，公司拟以实施权益分派股权登记日登记的总股本为基数，向全体 股东每 10 股派发现金红利 6.2 元（含税）。截至 2024 年 12 月 31 日，公司总股本 406,800,000 股，以此计算合计拟派发现金红利 252,216,000.00 元（含税），占合并 报表中归属于上市公司股东净利润的比例为 30.48%。2024 年度公司不送红股，不 每 ...

| 报告期指标 | 2024年年报 | 2023年年报 | 本年比上年增减(%) | 2022年年报 | | --- | --- | --- | --- | --- | | 基本每股收益（元） | 2.0300 | 1.3700 | 48.18 | 0.7100 | | 每股净资产（元） | 6.28 | 4.61 | 36.23 | 3.46 | | 每股公积金(元) | 1.02 | 0.98 | 4.08 | 0.98 | | 每股未分配利润(元) | 3.81 | 2.35 | 62.13 | 1.30 | | 每股经营现金流(元) | - | - | - | - | | 营业收入(亿元) | 28.17 | 21 | 34.14 | 15.27 | | 净利润(亿元) | 8.28 | 5.55 | 49.19 | 2.87 | | 净资产收益率(%) | 37.69 | 33.98 | 10.92 | 22.41 | 数据四舍五入，查看更多财务数据>> 一、主要会计数据和财务指标 | 名称 | 持有数量(万股) | 占总股本比例 | 增减情况(万 | | --- | --- | --- | --- ...

证券代码：688278 证券简称：特宝生物 公告编号：2025-006 厦门特宝生物工程股份有限公司 关于对外捐赠的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 厦门特宝生物工程股份有限公司（以下简称"公司"）于 2025 年 3 月 7 日召 开第九届董事会第六次会议，全票审议通过了《关于对外捐赠的议案》。公司决 定向中国肝炎防治基金会（以下简称"基金会"）捐赠人民币 900 万元，用于基 金会开展的乙肝病毒（HBV）相关肝癌高风险人群防治公益项目。根据《公司章 程》等规定，本次对外捐赠无需提交公司股东大会审议，不涉及关联交易，具体 情况如下： 一、 捐赠事项概况 三、本次捐赠对公司的影响 本次对外捐赠是公司积极履行社会责任、回馈社会的具体举措。本次对外捐 赠现金来源于自有资金，不会对当期及未来经营业绩构成重大影响，不存在损害 公司及全体股东特别是中小股东利益的情形。 四、最近十二个月内公司对外捐赠情况 董事会授权董事长及管理层在上述捐赠范围内办理与本次捐赠相关的协议 签署、捐赠款支付等所有事项。 二、本次捐赠的 ...

Financial Performance - Total revenue for 2024 reached CNY 281,715.82 million, a year-on-year increase of 34.13%[4] - Net profit attributable to shareholders was CNY 82,760.22 million, reflecting a growth of 49.00% compared to the previous year[6] - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 82,696.48 million, up 42.73% year-on-year[6] - Basic earnings per share increased to CNY 2.03, representing a growth of 48.18%[4] Assets and Equity - Total assets at the end of the reporting period were CNY 305,041.48 million, a 29.47% increase from the beginning of the period[6] - Shareholders' equity attributable to the parent company rose to CNY 255,331.63 million, marking a 36.08% increase[6] - The company's net asset per share attributable to shareholders increased to CNY 6.28, a rise of 36.23%[5] Growth Drivers - The significant growth in revenue and profit was primarily driven by stable sales of the key product, Pegbivac, and ongoing management reforms[7] - The company emphasizes the importance of ongoing clinical research for hepatitis B treatment in driving product recognition and sales growth[6] Financial Data Disclaimer - Investors are advised to note that the financial data presented is preliminary and subject to audit, with final figures to be disclosed in the annual report[9]

事件简评 2025 年 2 月 21 日，特宝生物发布公告，公司全资子公司厦门伯赛 基因转录技术有限公司拟以自有资金收购 Skyline Therapeutics Limited 部分资产，本次收购范围包括九天开曼及其下属公司的资 产（不包含其下属公司 Skyline Therapeutics (US) Inc.及其已 取得的资产或权利）。本次交易完成后，标的公司将成为伯赛基因 的全资子公司，纳入公司合并报表范围。 经营分析 标的公司深耕基因治疗，在研管线覆盖多个疾病领域。标的公司 拥有开发创新基因治疗的尖端核心技术和深厚的研发经验，自主 建立了尖端 AAV 基因治疗平台，涵盖 AAV 衣壳发现、载体设计和 构建等核心技术，依托该平台目前已有多个项目处于研发阶段，包 括新一代 SMN 基因替代疗法治疗脊髓性肌肉萎缩症（SMA）基因治 疗项目（处于临床研究阶段，临床批件号 2023LP02471），具有优 越肝脏靶向性治疗肝豆状核变性的基因疗法、治疗遗传性视网膜 病变的突破性眼科基因疗法、以及领先的遗传性心肌病基因疗法 等覆盖神经、代谢、眼科、心血管等疾病领域的管线产品。 收购基于整体业务布局，有望提升持续发展 ...

证券代码：688278 证券简称：特宝生物 公告编号：2025-004 厦门特宝生物工程股份有限公司 关于全资子公司收购 Skyline Therapeutics Limited 部分资产的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 厦门特宝生物工程股份有限公司（以下简称"公司"）的全资子公司厦门 伯赛基因转录技术有限公司（以下简称"伯赛基因"或"买方"）拟以自有资金 收购 Skyline Therapeutics Limited（以下简称"九天开曼"或"标的公司"）部分 资产，本次收购范围包括九天开曼及其下属公司的资产（不包含其下属公司 Skyline Therapeutics (US) Inc.及其已取得的资产或权利）。本次交易完成后，标的公司将 成为伯赛基因的全资子公司，纳入公司合并报表范围。 本次交易对价包含合并对价和附加合并对价，其中合并对价为 1500 万美 元；附加合并对价为在协议约定条件满足时，由最高不超过 4300 万美元的开发和 销售里程碑款，再许可提成和按年净销售额个位数百分 ...

Investment Rating - The report maintains a "Buy" rating for the company [4] Core Views - The company is expected to achieve a net profit attributable to shareholders of 8.10 to 8.40 billion RMB in 2024, representing a year-on-year growth of 46% to 51% [1] - The company's main product, Paigebin, is driving rapid growth in performance, supported by ongoing clinical research in hepatitis B treatment [2] - The company has expanded its clinical cure outpatient services for chronic hepatitis B, with 566 outpatient clinics established across 28 provincial regions in China [2] - Key projects in the liver disease field are progressing, with new indications for existing products receiving approval [3] Summary by Sections Performance Review - The company forecasts a net profit of 8.10 to 8.40 billion RMB for 2024, with a growth rate of 46% to 51% year-on-year [1] - For the first quarter of 2024, the expected net profit is between 2.55 to 2.85 billion RMB, reflecting a growth of 36% to 52% [1] Business Analysis - The main business is performing steadily, with Paigebin's volume driving significant growth [2] - The company is actively involved in various hepatitis B clinical cure and liver cancer prevention projects, with results being presented at major conferences [2] - The outpatient service for chronic hepatitis B is expanding, enhancing market education and management for patients [2] Key Projects and Pipeline - The company is advancing key projects in the liver disease sector, with new indications for existing products receiving IND approval [3] - Collaborations with other companies are enhancing the pipeline in the non-alcoholic fatty liver disease (NASH) area [3] Profit Forecast and Valuation - The company is projected to achieve net profits of 8.20 billion RMB (+48%), 11.08 billion RMB (+35%), and 14.18 billion RMB (+28%) for the years 2024 to 2026, respectively [4] - Corresponding EPS for these years are expected to be 2.02 RMB, 2.72 RMB, and 3.49 RMB, with P/E ratios of 36, 27, and 21 [4]

《科创板日报》1月15日讯（记者 邱思雨） 特宝生物主要从事重组蛋白质及其长效修饰药物研发、生产及销售。该公司核心产品派格宾（通用名： 聚乙二醇干扰素α-2b注射液）是由其自主研发的治疗病毒性肝炎的国家1类新药。派格宾于2016年10月 获批上市，获批适应症为"用于治疗慢性丙型肝炎成年患者"，2017年9月获得增加适应症"适用于治疗成 人慢性乙型肝炎"的补充申请注册批件。 就慢性乙肝门诊趋势方面，自早期科学数据积累，到2018年形成行业专家共识，直至2023年国家卫健委 医院管理研究所等单位在全国启动"乙肝临床治愈门诊规范化建设与能力提升项目"，越来越多医院设立 慢乙肝临床治愈门诊。 特宝生物表示，随着慢乙肝防治指南的不断升级和临床治愈科学证据的不断积累，将推动认知不断提 升，接受治疗的患者数量将呈上升趋势。 不过，特宝生物也表明，干扰素是通过调动人体的免疫功能和抗病毒作用来治疗改善疾病，由于其生理 学特性，干扰素存在流感样症状等常见不良反应，相比核苷（酸）类似物，患者治疗和管理有更大的工 作量，药物的优化使用需要更多的临床使用经验，这些因素可能对医患的治疗选择造成影响。 今日（1月15日）晚间，特宝生物发布 ...

Financial Performance Forecast - The company expects a net profit attributable to shareholders of the parent company for 2024 to be between 810 million and 840 million CNY, representing a year-on-year increase of 25.46 million to 28.46 million CNY, or a growth of 45.83% to 51.23%[4] - The projected net profit attributable to shareholders after deducting non-recurring gains and losses is estimated to be between 805 million and 835 million CNY, reflecting an increase of 22.56 million to 25.56 million CNY, or a growth of 38.94% to 44.12% compared to the previous year[4] - In 2023, the company achieved a total profit of 640.65 million CNY and a net profit attributable to shareholders of 555.45 million CNY, with a basic earnings per share of 1.37 CNY[5] Business Stability and Growth - The company's main business remains stable and is expected to grow significantly due to the increasing recognition of its product, Pegbivac, as a first-line antiviral treatment for chronic hepatitis B[6] Performance Forecast Validity - The performance forecast is based on preliminary calculations by the company's finance department and has not yet been audited by a registered accountant[7] - The company has not identified any significant uncertainties that could affect the accuracy of the performance forecast[7] - Investors are advised that the forecast data is preliminary and the final audited financial data will be disclosed in the official annual report for 2024[8]